[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100434084":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":34,"responsibleParty":94,"collaborators":11,"id":96,"slug":11,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":97,"sex":102,"minAge":103,"maxAge":11,"enrollmentInfo":104,"targetDuration":11,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":37,"whyStopped":11,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},{"fullName":5,"class":6},"Gustave Roussy, Cancer Campus, Grand Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"solid tumor or hematological malignancy","EXPERIMENTAL",null,[13],"Procedure: Biopsy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"PROCEDURE","Biopsy","Blood and tumor samples for Genetic Profiling research",[9],[21],{"name":22,"affiliation":5,"role":23},"Antoine Italiano, MD PhD","PRINCIPAL_INVESTIGATOR",[25,30],{"name":22,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","+33 (0)1 42 11 42 11","34 71","antoine.italiano@gustaveroussy.fr",{"name":31,"role":26,"phone":32,"phoneExt":11,"email":33},"Clementine MAHAUT","+33 (0)1 42 11 23 34","clementine.mahaut@gustaveroussy.fr",[35,52,65,80],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Gustave Roussy Cancer Campus Grand Paris","RECRUITING","Villejuif","Val de Marne","94805","France",{"type":43,"coordinates":44},"Point",[45,46],2.35992,48.7939,{"lat":46,"lon":45},[49,50],{"name":22,"role":26,"phone":27,"phoneExt":11,"email":29},{"name":51,"role":26,"phone":32,"phoneExt":11,"email":33},"Clementine Mahaut, PhD",{"facility":53,"status":37,"city":54,"state":11,"zip":55,"country":41,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Hôpital Marie-Lannelongue","Le Plessis-Robinson","92350",{"type":43,"coordinates":57},[58,59],2.27078,48.78889,{"lat":59,"lon":58},[62],{"name":63,"role":26,"phone":11,"phoneExt":11,"email":64},"Olaf MERCIER, Pr","olaf.mercier@universite-paris-saclay.fr",{"facility":66,"status":67,"city":68,"state":11,"zip":69,"country":41,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Hôpital Saint-Joseph","NOT_YET_RECRUITING","Paris","75014",{"type":43,"coordinates":71},[72,73],2.3488,48.85341,{"lat":73,"lon":72},[76],{"name":77,"role":26,"phone":78,"phoneExt":11,"email":79},"Charles NALTET, Dr","01 44 12 37 52","cnaltet@ghpsj.fr",{"facility":81,"status":67,"city":82,"state":11,"zip":83,"country":41,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"Hôpital Foch","Suresnes","92150",{"type":43,"coordinates":85},[86,87],2.22929,48.87143,{"lat":87,"lon":86},[90],{"name":91,"role":26,"phone":92,"phoneExt":11,"email":93},"Alexandra BIZOT, Dr","01 46 25 45 02","a.bizot@hopital-foch.com",{"type":95,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100434084",false,"NCT04932525","Gustave Roussy Cancer Profiling","STING","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Histology: solid malignant tumor or hematological malignancy.\n3. Patient with a social security in compliance with the French law relating to biomedical research (Article L.1121-11 of French Public Health Code)\n4. Voluntary signed and dated written informed consent prior to any study specific procedure.\n\nExclusion Criteria:\n\n1. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in a clinical trial or which would jeopardize compliance with the protocol\n2. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent\n3. Pregnant or breast-feeding women\n4. Minors (Age \\\u003C 18 years)","ALL","18 Years",{"count":105,"type":106},20000,"ESTIMATED","INTERVENTIONAL",[109],"NA","The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +\u002F- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.",[112],"Solid Tumor, Unspecified, Adult",[114,115],"immunological profiling","targetable oncogenic aberration","2026-02-05",{"date":118,"type":119},"2026-02-06","ACTUAL",{"date":121,"type":119},"2021-05-10",{"date":123,"type":106},"2033-05-10",{"name":5,"class":6},4]